News
Genomic assays play a critical role in guiding treatment decisions for patients with early-stage invasive breast cancer by providing prognostic and predictive insights. In a live Community Case Forum ...
Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback